Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label case series

Journal of Rheumatology

Volumn 39, Issue 4, 2012, Pages 864-867

  Mori, Masaaki ^a   Imagawa, Tomoyuki ^a   Hara, Ryoki ^a   Kikuchi, Masako ^a   Hara, Takuma ^a   Nozawa, Tomo ^a   Miyamae, Takako ^a   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Infliximab; Intravenous immunoglobulin therapy; Kawasaki disease; Plasma exchange; Proinflammatory cytokine

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN; INFLIXIMAB;

ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT OUTCOME;

EID: 84859464707     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110877     Document Type: Article

References (14)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
2. Kobayashi N, Mori M, Kobayashi Y, Miyamae T, Imagawa T, Okuyama T, et al. Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease. Mod Rheumatol 2004;14:447-52. (Pubitemid 40028668)
3. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. (Pubitemid 40616253)
4. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833-8.
5. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kioyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (5th revised edition). Pediatr Intern 2005;47:232-4.
6. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80. (Pubitemid 30659223)
7. Imagawa T, Mori M, Miyamae T, Ito S, Nakamura T, Yasui K, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263-4. (Pubitemid 38657183)
8. Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama K, Ito S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004;14:43-7. (Pubitemid 40796159)
9. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7. (Pubitemid 32640933)
10. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-75.
11. Miura M, Ohki H, Yoshiba S, Ueda H, Sugaya A, Satoh M, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096-7. (Pubitemid 41406624)
12. Leung DYM, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986;164:1958-72. (Pubitemid 17217976)
13. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
14. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure. Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation 2003;107:3133-40. (Pubitemid 36793081)